Trial Profile
A Phase II/III Study of Sargramostim in Patients With Coronavirus Disease-2019 (COVID-19)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary)
- Indications COVID-19 pneumonia
- Focus Registrational; Therapeutic Use
- Sponsors Nobelpharma
- 01 Nov 2021 Status changed from recruiting to completed.
- 05 May 2021 Inclusion criteria has been updated to increase the maximum age limit from 80 years to 85 years.
- 09 Feb 2021 Planned End Date changed from 30 Apr 2021 to 31 Oct 2021.